[go: up one dir, main page]

CN116134139A - 一种转基因免疫效应细胞及其应用 - Google Patents

一种转基因免疫效应细胞及其应用 Download PDF

Info

Publication number
CN116134139A
CN116134139A CN202280005529.5A CN202280005529A CN116134139A CN 116134139 A CN116134139 A CN 116134139A CN 202280005529 A CN202280005529 A CN 202280005529A CN 116134139 A CN116134139 A CN 116134139A
Authority
CN
China
Prior art keywords
immune effector
effector cell
chemokine receptor
seq
transgenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280005529.5A
Other languages
English (en)
Inventor
叶立军
彭亮
王先进
黄倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Fapon Biological Therapy Co ltd
Original Assignee
Shenzhen Fapon Biological Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Fapon Biological Therapy Co ltd filed Critical Shenzhen Fapon Biological Therapy Co ltd
Publication of CN116134139A publication Critical patent/CN116134139A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4236—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

涉及生物技术领域，具体涉及一种转基因免疫效应细胞及其应用。该免疫效应细胞表达的融合蛋白中的免疫检查点抗体能解除免疫检查点对免疫效应细胞的免疫抑制，细胞因子能增强免疫效应细胞的抗肿瘤活性，趋化因子受体分子使得免疫效应细胞向肿瘤部位的迁移能力显著提高；与融合蛋白、以及共表达上述融合蛋白和嵌合抗原受体的细胞相比，该免疫效应细胞对肿瘤细胞具有更强的杀伤效果，药物毒性低，安全性高，有效实现了CART对实体瘤的精准治疗。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202280005529.5A 2021-09-09 2022-09-08 一种转基因免疫效应细胞及其应用 Pending CN116134139A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111055628 2021-09-09
CN2021110556288 2021-09-09
PCT/CN2022/117831 WO2023036246A1 (zh) 2021-09-09 2022-09-08 一种转基因免疫效应细胞及其应用

Publications (1)

Publication Number Publication Date
CN116134139A true CN116134139A (zh) 2023-05-16

Family

ID=85507188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280005529.5A Pending CN116134139A (zh) 2021-09-09 2022-09-08 一种转基因免疫效应细胞及其应用

Country Status (3)

Country Link
CN (1) CN116134139A (zh)
TW (1) TW202330909A (zh)
WO (1) WO2023036246A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117535324A (zh) * 2023-11-24 2024-02-09 上海恩凯细胞技术有限公司 多功能基因修饰的免疫细胞及其制备方法和应用
CN117587014A (zh) * 2023-11-24 2024-02-23 上海恩凯细胞技术有限公司 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用
CN120192926A (zh) * 2025-03-21 2025-06-24 广东药科大学附属第一医院 用于治疗非小细胞肺癌和/或食管鳞癌的car-nk细胞及其应用和组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108610420A (zh) * 2016-12-13 2018-10-02 科济生物医药（上海）有限公司 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
CN110144327A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性抗肿瘤t细胞及其制备方法和应用
CN110536700A (zh) * 2017-04-19 2019-12-03 南加利福尼亚大学 用于治疗癌症的组合物和方法
CN112368015A (zh) * 2018-06-18 2021-02-12 安维达生物科技公司 细胞因子融合蛋白及其用途
CN112961248A (zh) * 2021-02-22 2021-06-15 广州百暨基因科技有限公司 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499766B (zh) * 2020-04-24 2022-11-04 中国医学科学院血液病医院(中国医学科学院血液学研究所) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
WO2022007804A1 (zh) * 2020-07-07 2022-01-13 深圳市菲鹏生物治疗股份有限公司 T淋巴细胞及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108610420A (zh) * 2016-12-13 2018-10-02 科济生物医药（上海）有限公司 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
CN110536700A (zh) * 2017-04-19 2019-12-03 南加利福尼亚大学 用于治疗癌症的组合物和方法
CN110144327A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性抗肿瘤t细胞及其制备方法和应用
CN112368015A (zh) * 2018-06-18 2021-02-12 安维达生物科技公司 细胞因子融合蛋白及其用途
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
CN112961248A (zh) * 2021-02-22 2021-06-15 广州百暨基因科技有限公司 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
2ND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY: "CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma", 2ND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY, 20 March 2020 (2020-03-20), pages 2 *
HONG LUO等: "Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion", CLIN CANCER RES, vol. 26, no. 20, 15 October 2020 (2020-10-15), pages 5494 - 5505, XP055921328, DOI: 10.1158/1078-0432.CCR-20-0777 *
RAFIQ S等: "Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo", NATURE BIOTECHNOLOGY, vol. 36, no. 9, 13 August 2018 (2018-08-13) *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117535324A (zh) * 2023-11-24 2024-02-09 上海恩凯细胞技术有限公司 多功能基因修饰的免疫细胞及其制备方法和应用
CN117587014A (zh) * 2023-11-24 2024-02-23 上海恩凯细胞技术有限公司 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用
CN117587014B (zh) * 2023-11-24 2025-01-24 上海恩凯细胞技术有限公司 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用
CN117535324B (zh) * 2023-11-24 2025-05-23 上海恩凯细胞技术有限公司 多功能基因修饰的免疫细胞及其制备方法和应用
WO2025108480A1 (zh) * 2023-11-24 2025-05-30 上海恩凯细胞技术有限公司 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用
CN120192926A (zh) * 2025-03-21 2025-06-24 广东药科大学附属第一医院 用于治疗非小细胞肺癌和/或食管鳞癌的car-nk细胞及其应用和组合物

Also Published As

Publication number Publication date
TW202330909A (zh) 2023-08-01
WO2023036246A1 (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
CN116134139A (zh) 一种转基因免疫效应细胞及其应用
Conlon et al. Cytokines in the treatment of cancer
US12410248B2 (en) Chimeric antigen receptor and its use
CN110437339B (zh) 一种以白介素15为活性成分的融合蛋白型药物前体
KR102322510B1 (ko) 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
JP2025100669A (ja) 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
US20040072299A1 (en) Multiple cytokine protein complexes
US10603358B2 (en) Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
WO2009117117A1 (en) T cell receptor fusions and conjugates and methods of use there of
TW201841944A (zh) 4-1bbl變異體及包含其之融合蛋白
Bergamaschi et al. Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells
JP2019510786A (ja) 免疫療法におけるＴＧＦβの阻害
WO2022089601A1 (zh) 一种il-2与抗体亚单位构成的双功能融合蛋白
JPWO2019246508A5 (zh)
JP4635255B2 (ja) 抗体医薬
US20250302875A1 (en) TARGETING MODULES AGAINST IL13R-alpha-2 AND/OR HER2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR-MEDIATED IMMUNE RESPONSE IN A MAMMAL
MOOSMAYER et al. Characterization of different soluble TNF receptor (TNFR80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity
JP7748284B2 (ja) Ｔ細胞受容体及びその使用方法
US20210008167A1 (en) T cell receptor fusions and conjugates and methods of use thereof
CN112566926A (zh) Tnf型受体-配体融合蛋白及方法
EP4296281A1 (en) Targeting modules against cd123 and a tag for use in a method for stimulating a universal chimeric antigen receptor-mediated immune response in a mammal
KR20210149048A (ko) T 세포 수용체 및 이의 사용 방법
EP4566619A1 (en) Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal
CN115197326B (zh) 融合蛋白及其编码基因和重组载体以及它们的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40086570

Country of ref document: HK